A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Public ClinicalTrials.gov record NCT07503808. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.
Study identification
- NCT ID
- NCT07503808
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 150 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 23, 2026
- Primary completion
- Jul 29, 2027
- Completion
- Jul 29, 2027
- Last update posted
- Jun 17, 2026
2026 – 2027
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sarah Cannon Research Institute at HealthONE | Denver | Colorado | 80218 | Recruiting |
| Florida Cancer Specialists | Sarasota | Florida | 34232 | Recruiting |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | Recruiting |
| START New York Long Island, LLC | Lake Success | New York | 11042 | Recruiting |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | Recruiting |
| NEXT Texas LLC - Austin | Austin | Texas | 78758 | Recruiting |
| START Dallas Fort Worth, LLC | Fort Worth | Texas | 76104 | Recruiting |
| MD Anderson | Houston | Texas | 77030 | Recruiting |
| NEXT Texas LLC - Houston | Houston | Texas | 77054 | Recruiting |
| NEXT Texas LLC - Dallas | Irving | Texas | 75039 | Recruiting |
| NEXT Texas LLC - San Antonio | San Antonio | Texas | 78229 | Recruiting |
| START San Antonio, LLC | San Antonio | Texas | 78229 | Recruiting |
| START Mountain Region, LLC | West Valley City | Utah | 84119 | Recruiting |
| NEXT Texas LLC - Virginia | Fairfax | Virginia | 22031 | Recruiting |
| Medical Oncology Associates | Spokane | Washington | 99208 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07503808, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 17, 2026 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07503808 live on ClinicalTrials.gov.